PUBLISHER: TechSci Research | PRODUCT CODE: 1174488
PUBLISHER: TechSci Research | PRODUCT CODE: 1174488
Adalimumab Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Type, By Product Type, By Therapeutic Area, By Distribution Channel, By End Users, By Region, Forecast & Opportunities, 2028
We offer 8 hour analyst time for an additional research. Please contact us for the details.
Global adalimumab market is expected to undergo significant growth during the forecast period, 2024-2028. The rising prevalence of arthritis coupled with large number of clinical trials is impelling the growth of the market. Adalimumab is an anti-TNF drug which is used for the treatment of rheumatoid arthritis, psoriatic arthritis, psoriasis and ulcerative colitis. Adalimumab lowers the chances of inflammatory response by binding to a TNFα. Adalimumab are currently being marketed in over 60 countries around the world.
Several companies are undergoing extensive clinical trials and R&D activities, which in turn, is expected to augment a major growth factor for global adalimumab market. The reimbursement coverage and well-defined regulatory guidelines are further expected to fuel the market growth through 2028. However, patent expiration of blockbuster drugs is expected to slow down the market growth. Besides, side effects associated with the drugs is expected to restrain the growth of the market.
Global adalimumab market is segmented based on based on type, product type, therapeutic area, distribution channel, end user, company and region. Based on therapeutic area, the market is categorized into rheumatoid arthritis, psoriatic arthritis, psoriasis, Crohn's disease, and others. Among them, the rheumatoid arthritis is expected to dominate the global market owing to high prevalence among elderly population.
Regionally, North America is expected to dominate the global adalimumab market followed by Europe. The advanced healthcare infrastructure and well-organized regulatory framework in these two regions is making them a lucrative market for adalimumab manufacturers.
Major companies operating in global adalimumab market include Abbvie Inc., Pfizer Inc., Amgen Inc., Novartis AG, Torrent Pharmaceuticals Ltd., Cadila Healthcare Ltd, Boehringer Ingelheim International GmbH, Mylan N.V., Hetero Biopharma Ltd., and Samsung Bioepis Co Ltd. The market players are undergoing extensive clinical trials to test the safety and efficacy of the adalimumab in treatment of various diseases.
Objective of the Study
- To analyse and forecast the market size of global adalimumab market.
- To forecast global adalimumab market based on based on type, product type, therapeutic area, distribution channel, end user, company and region.
- To identify drivers and challenges for global adalimumab market.
- To examine competitive developments such as expansions, new product launches, mergers & acquisitions etc. in global adalimumab market.
- To identify and analyse the profile of leading players operating in the global adalimumab market.
TechSci Research performed both primary as well as exhaustive secondary research for this study. Initially, TechSci Research sourced a list of adalimumab manufacturing companies across the globe. Subsequently, TechSci Research conducted primary research surveys with the identified companies. While interviewing, the respondents were also enquired about their competitors. Through this technique, TechSci Research could include the companies which could not be identified due to the limitations of secondary research.
TechSci Research calculated global adalimumab market size using a bottom-up approach, where data for various end user industries and its application across various product types were recorded and forecast for the future years. TechSci Research sourced these values from the industry experts and company representatives and externally validated through analysing historical data of these product types and applications for getting an appropriate, overall market size. Various secondary sources such as company websites, news articles, press releases, company annual reports, investor presentations and financial reports were also used by TechSci Research.
Key Target Audience:
- Adalimumab manufacturers, companies, partners, hospitals pharmacy/retail pharmacy and other stakeholders
- Government bodies such as regulating authorities and policy makers
- Organizations, industry associations, forums and alliances related to adalimumab
- Market research and consulting firms
The study is useful in providing answers to several critical questions that are important for the industry stakeholders such as adalimumab manufacturing companies, end users etc., besides allowing them in strategizing investments and capitalizing on market opportunities.
Report Scope
In this report, global adalimumab market has been segmented into following categories, in addition to the industry trends which have also been detailed below:
Global Adalimumab Market, By Type:
- Biologics
- Biosimilar
Global Adalimumab Market, By Product Type:
- Branded
- Generics
Global Adalimumab Market, By Therapeutic Area:
- Rheumatoid Arthritis
- Psoriatic Arthritis
- Psoriasis
- Crohn's Disease
- Others
Global Adalimumab Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Others
Global Adalimumab Market, By End User:
- Hospitals & Clinics
- Home Healthcare
- Others
Global Adalimumab Market, By Region:
- Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- Europe
- France
- Germany
- United Kingdom
- Italy
- Spain
- North America
- United States
- Mexico
- Canada
- South America
- Brazil
- Argentina
- Colombia
- Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in global adalimumab market.
Available Customizations
With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
- Detailed analysis and profiling of additional market players (up to five).
Profit Margin Analysis
- Profit margin analysis in case of direct and indirect sales channel.
Table of Contents
1. Product Overview
- 1.1. Market Definition
- 1.2. Scope of the Market
- 1.2.1. Markets Covered
- 1.2.2. Years Considered for Study
- 1.2.3. Key Market Segmentations
2. Research Methodology
- 2.1. Objective of the Study
- 2.2. Baseline Methodology
- 2.3. Key Industry Partners
- 2.4. Major Association and Secondary Sources
- 2.5. Forecasting Methodology
- 2.6. Data Triangulation & Validation
- 2.7. Assumptions and Limitations
3. Executive Summary
- 3.1. Overview of the Market
- 3.2. Overview of Key Market Segmentations
- 3.3. Overview of Key Market Players
- 3.4. Overview of Key Regions/Countries
- 3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
- 4.1. Adalimumab Demand, By Therapeutic Area
- 4.2. Adalimumab Demand, By Region
- 4.3. Adalimumab Demand, By Gender
- 4.4. Adalimumab Demand, By Patient Population
- 4.5. Commonly Observed Side-Effects
- 4.6. Brand Awareness
5. Pharmacodynamic Overview of Adalimumab
- 5.1. Mechanism of Action
- 5.2. Absorption
- 5.3. Volume of Distribution
- 5.4. Route of Elimination
- 5.5. Half Life
- 5.6. Clearance
- 5.7. Toxicity
6. Clinical Trials
- 6.1. Ongoing Clinical Trials
- 6.2. Completed Clinical Trials
- 6.3. Terminated Clinical Trials
- 6.4. Clinical Trial Analysis
7. Patent Analysis
- 7.1. Patent Granted
- 7.2. Patent Applications Filed
8. Global Adalimumab Market Outlook
- 8.1. Market Size & Forecast
- 8.1.1. By Value
- 8.2. Market Share & Forecast
- 8.2.1. By Type (Biologics v/s Biosimilars)
- 8.2.2. By Product Type (Branded v/s Generics)
- 8.2.3. By Therapeutic Area (Rheumatoid Arthritis, Psoriatic Arthritis, Psoriasis, Crohn's Disease, Others)
- 8.2.4. Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Others)
- 8.2.5. By End User (Hospitals & Clinics, Home Healthcare, Others)
- 8.2.6. By Company (2022)
- 8.2.7. By Region
- 8.3. Product Market Map
9. North America Adalimumab Market Outlook
- 9.1. Market Size & Forecast
- 9.1.1. By Value & Volume
- 9.2. Market Share & Forecast
- 9.2.1. By Type
- 9.2.2. By Product Type
- 9.2.3. By Therapeutic Area
- 9.2.4. By Distribution Channel
- 9.2.5. By End User
- 9.2.6. By Country
- 9.3. North America: Country Analysis
- 9.3.1. United States Adalimumab Market Outlook
- 9.3.1.1. Market Size & Forecast
- 9.3.1.1.1. By Value
- 9.3.1.2. Market Share & Forecast
- 9.3.1.2.1. By Type
- 9.3.1.2.2. By Product Type
- 9.3.1.2.3. By Therapeutic Area
- 9.3.1.2.4. By Distribution Channel
- 9.3.1.2.5. By End User
- 9.3.1.1. Market Size & Forecast
- 9.3.2. Mexico Adalimumab Market Outlook
- 9.3.2.1. Market Size & Forecast
- 9.3.2.1.1. By Value
- 9.3.2.2. Market Share & Forecast
- 9.3.2.2.1. By Type
- 9.3.2.2.2. By Product Type
- 9.3.2.2.3. By Therapeutic Area
- 9.3.2.2.4. By Distribution Channel
- 9.3.2.2.5. By End User
- 9.3.2.1. Market Size & Forecast
- 9.3.3. Canada Adalimumab Market Outlook
- 9.3.3.1. Market Size & Forecast
- 9.3.3.1.1. By Value
- 9.3.3.2. Market Share & Forecast
- 9.3.3.2.1. By Type
- 9.3.3.2.2. By Product Type
- 9.3.3.2.3. By Therapeutic Area
- 9.3.3.2.4. By Distribution Channel
- 9.3.3.2.5. By End User
- 9.3.3.1. Market Size & Forecast
- 9.3.1. United States Adalimumab Market Outlook
10. Europe Adalimumab Market Outlook
- 10.1. Market Size & Forecast
- 10.1.1. By Value & Volume
- 10.2. Market Share & Forecast
- 10.2.1. By Type
- 10.2.2. By Product Type
- 10.2.3. By Therapeutic Area
- 10.2.4. By Distribution Channel
- 10.2.5. By End User
- 10.2.6. By Country
- 10.3. Europe: Country Analysis
- 10.3.1. France Adalimumab Market Outlook
- 10.3.1.1. Market Size & Forecast
- 10.3.1.1.1. By Value
- 10.3.1.2. Market Share & Forecast
- 10.3.1.2.1. By Type
- 10.3.1.2.2. By Product Type
- 10.3.1.2.3. By Therapeutic Area
- 10.3.1.2.4. By Distribution Channel
- 10.3.1.2.5. By End User
- 10.3.1.1. Market Size & Forecast
- 10.3.2. Germany Adalimumab Market Outlook
- 10.3.2.1. Market Size & Forecast
- 10.3.2.1.1. By Value
- 10.3.2.2. Market Share & Forecast
- 10.3.2.2.1. By Type
- 10.3.2.2.2. By Product Type
- 10.3.2.2.3. By Therapeutic Area
- 10.3.2.2.4. By Distribution Channel
- 10.3.2.2.5. By End User
- 10.3.2.1. Market Size & Forecast
- 10.3.3. United Kingdom Adalimumab Market Outlook
- 10.3.3.1. Market Size & Forecast
- 10.3.3.1.1. By Value
- 10.3.3.2. Market Share & Forecast
- 10.3.3.2.1. By Type
- 10.3.3.2.2. By Product Type
- 10.3.3.2.3. By Therapeutic Area
- 10.3.3.2.4. By Distribution Channel
- 10.3.3.2.5. By End User
- 10.3.3.1. Market Size & Forecast
- 10.3.4. Italy Adalimumab Market Outlook
- 10.3.4.1. Market Size & Forecast
- 10.3.4.1.1. By Value
- 10.3.4.2. Market Share & Forecast
- 10.3.4.2.1. By Type
- 10.3.4.2.2. By Product Type
- 10.3.4.2.3. By Therapeutic Area
- 10.3.4.2.4. By Distribution Channel
- 10.3.4.2.5. By End User
- 10.3.4.1. Market Size & Forecast
- 10.3.5. Spain Adalimumab Market Outlook
- 10.3.5.1. Market Size & Forecast
- 10.3.5.1.1. By Value
- 10.3.5.2. Market Share & Forecast
- 10.3.5.2.1. By Type
- 10.3.5.2.2. By Product Type
- 10.3.5.2.3. By Therapeutic Area
- 10.3.5.2.4. By Distribution Channel
- 10.3.5.2.5. By End User
- 10.3.5.1. Market Size & Forecast
- 10.3.1. France Adalimumab Market Outlook
11. Asia-Pacific Adalimumab Market Outlook
- 11.1. Market Size & Forecast
- 11.1.1. By Value & Volume
- 11.2. Market Share & Forecast
- 11.2.1. By Type
- 11.2.2. By Product Type
- 11.2.3. By Therapeutic Area
- 11.2.4. By Distribution Channel
- 11.2.5. By End User
- 11.2.6. By Country
- 11.3. Asia-Pacific: Country Analysis
- 11.3.1. China Adalimumab Market Outlook
- 11.3.1.1. Market Size & Forecast
- 11.3.1.1.1. By Value
- 11.3.1.2. Market Share & Forecast
- 11.3.1.2.1. By Type
- 11.3.1.2.2. By Product Type
- 11.3.1.2.3. By Therapeutic Area
- 11.3.1.2.4. By Distribution Channel
- 11.3.1.2.5. By End User
- 11.3.1.1. Market Size & Forecast
- 11.3.2. India Adalimumab Market Outlook
- 11.3.2.1. Market Size & Forecast
- 11.3.2.1.1. By Value
- 11.3.2.2. Market Share & Forecast
- 11.3.2.2.1. By Type
- 11.3.2.2.2. By Product Type
- 11.3.2.2.3. By Therapeutic Area
- 11.3.2.2.4. By Distribution Channel
- 11.3.2.2.5. By End User
- 11.3.2.1. Market Size & Forecast
- 11.3.3. South Korea Adalimumab Market Outlook
- 11.3.3.1. Market Size & Forecast
- 11.3.3.1.1. By Value
- 11.3.3.2. Market Share & Forecast
- 11.3.3.2.1. By Transgenic Crop
- 11.3.3.2.2. By Technique
- 11.3.3.2.3. By Application
- 11.3.3.2.4. By End User
- 11.3.3.1. Market Size & Forecast
- 11.3.4. Japan Adalimumab Market Outlook
- 11.3.4.1. Market Size & Forecast
- 11.3.4.1.1. By Value
- 11.3.4.2. Market Share & Forecast
- 11.3.4.2.1. By Type
- 11.3.4.2.2. By Product Type
- 11.3.4.2.3. By Therapeutic Area
- 11.3.4.2.4. By Distribution Channel
- 11.3.4.2.5. By End User
- 11.3.4.1. Market Size & Forecast
- 11.3.5. Australia Adalimumab Market Outlook
- 11.3.5.1. Market Size & Forecast
- 11.3.5.1.1. By Value
- 11.3.5.2. Market Share & Forecast
- 11.3.5.2.1. By Type
- 11.3.5.2.2. By Product Type
- 11.3.5.2.3. By Therapeutic Area
- 11.3.5.2.4. By Distribution Channel
- 11.3.5.2.5. By End User
- 11.3.5.1. Market Size & Forecast
- 11.3.1. China Adalimumab Market Outlook
12. South America Adalimumab Market Outlook
- 12.1. Market Size & Forecast
- 12.1.1. By Value & Volume
- 12.2. Market Share & Forecast
- 12.2.1. By Type
- 12.2.2. By Product Type
- 12.2.3. By Therapeutic Area
- 12.2.4. By Distribution Channel
- 12.2.5. By End User
- 12.2.6. By Country
- 12.3. South America: Country Analysis
- 12.3.1. Brazil Adalimumab Market Outlook
- 12.3.1.1. Market Size & Forecast
- 12.3.1.1.1. By Value
- 12.3.1.2. Market Share & Forecast
- 12.3.1.2.1. By Type
- 12.3.1.2.2. By Product Type
- 12.3.1.2.3. By Therapeutic Area
- 12.3.1.2.4. By Distribution Channel
- 12.3.1.2.5. By End User
- 12.3.1.1. Market Size & Forecast
- 12.3.2. Argentina Adalimumab Market Outlook
- 12.3.2.1. Market Size & Forecast
- 12.3.2.1.1. By Value
- 12.3.2.2. Market Share & Forecast
- 12.3.2.2.1. By Type
- 12.3.2.2.2. By Product Type
- 12.3.2.2.3. By Therapeutic Area
- 12.3.2.2.4. By Distribution Channel
- 12.3.2.2.5. By End User
- 12.3.2.1. Market Size & Forecast
- 12.3.3. Colombia Adalimumab Market Outlook
- 12.3.3.1. Market Size & Forecast
- 12.3.3.1.1. By Value
- 12.3.3.2. Market Share & Forecast
- 12.3.3.2.1. By Type
- 12.3.3.2.2. By Product Type
- 12.3.3.2.3. By Therapeutic Area
- 12.3.3.2.4. By Distribution Channel
- 12.3.3.2.5. By End User
- 12.3.3.1. Market Size & Forecast
- 12.3.1. Brazil Adalimumab Market Outlook
13. Middle East and Africa Adalimumab Market Outlook
- 13.1. Market Size & Forecast
- 13.1.1. By Value & Volume
- 13.2. Market Share & Forecast
- 13.2.1. By Type
- 13.2.2. By Product Type
- 13.2.3. By Therapeutic Area
- 13.2.4. By Distribution Channel
- 13.2.5. By End User
- 13.2.6. By Country
- 13.3. MEA: Country Analysis
- 13.3.1. South Africa Adalimumab Market Outlook
- 13.3.1.1. Market Size & Forecast
- 13.3.1.1.1. By Value
- 13.3.1.2. Market Share & Forecast
- 13.3.1.2.1. By Type
- 13.3.1.2.2. By Product Type
- 13.3.1.2.3. By Therapeutic Area
- 13.3.1.2.4. By Distribution Channel
- 13.3.1.2.5. By End User
- 13.3.1.1. Market Size & Forecast
- 13.3.2. Saudi Arabia Adalimumab Market Outlook
- 13.3.2.1. Market Size & Forecast
- 13.3.2.1.1. By Value
- 13.3.2.2. Market Share & Forecast
- 13.3.2.2.1. By Type
- 13.3.2.2.2. By Product Type
- 13.3.2.2.3. By Therapeutic Area
- 13.3.2.2.4. By Distribution Channel
- 13.3.2.2.5. By End User
- 13.3.2.1. Market Size & Forecast
- 13.3.3. UAE Adalimumab Market Outlook
- 13.3.3.1. Market Size & Forecast
- 13.3.3.1.1. By Value
- 13.3.3.2. Market Share & Forecast
- 13.3.3.2.1. By Type
- 13.3.3.2.2. By Product Type
- 13.3.3.2.3. By Therapeutic Area
- 13.3.3.2.4. By Distribution Channel
- 13.3.3.2.5. By End User
- 13.3.3.1. Market Size & Forecast
- 13.3.1. South Africa Adalimumab Market Outlook
14. Market Dynamics
- 14.1. Drivers
- 14.2. Challenges
15. Market Trends & Developments
16. Competitive Landscape
- 16.1. Abbvie Inc.
- 16.2. Pfizer, Inc.
- 16.3. Amgen Inc.
- 16.4. Novartis AG
- 16.5. Torrent Pharmaceuticals Ltd.
- 16.6. Cadila Healthcare Limited
- 16.7. Boehringer Ingelheim International GmbH
- 16.8. Mylan N.V.
- 16.9. Hetero Biopharma Ltd
- 16.10. Samsung Bioepis Co Ltd.
17. Strategic Recommendations
18. About Us & Disclaimer
